Aurobindo Pharma has informed stock exchanges that the United States Food and Drug Administration (US FDA) has classified the inspection of Eugia Pharma Specialities Limited's Unit-III facility as Official Action Indicated (OAI).
Eugia Pharma Specialities is a wholly owned subsidiary of Aurobindo Pharma.
The US FDA inspected Eugia Unit-III, a formulation manufacturing facility located at Pashamylaram in Telangana, between January 27 and February 6, 2026.
The inspection concluded with 11 observations, following which the regulator has now classified the facility under the OAI category.
The inspected facility belongs to Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma.
The manufacturing unit is located in Sangareddy district, Telangana, and is engaged in formulation manufacturing activities.
According to the company's disclosure, it received communication regarding the OAI classification on June 12, 2026.
The US FDA's classification follows its review of the observations issued during the inspection.
Aurobindo Pharma stated that there is no impact on the company's financial performance or operations as a result of the FDA action.
The company also reiterated its commitment to maintaining quality manufacturing standards across its facilities.
As of 12 June 2026, Aurobindo Pharma share price was closed at ₹1,468.00 per share, reflecting a surge of 0.27% from the previous close.
The US FDA has classified the inspection of Eugia Pharma Specialities' Unit-III manufacturing facility as Official Action Indicated (OAI) following an inspection conducted earlier this year. The company has stated that the classification does not have any impact on its financials or operations.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jun 13, 2026, 5:43 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
